Pediatric Pseudo-pseudoxanthoma Elasticum Resulting From D-Penicillamine Treatment for Wilson Disease

J Pediatr Gastroenterol Nutr. 2020 Dec;71(6):731-733. doi: 10.1097/MPG.0000000000002888.

Abstract

We describe a 14-year-old boy with Wilson disease (WD) who first developed pseudo-pseudoxanthoma elasticum (PPXE) after 4.5 years of treatment with D-penicillamine. Although previously reported cases have occurred in adults following at least a decade of high-dose D-penicillamine use, this case demonstrates that D-penicillamine-induced PPXE can present in children with shorter treatment courses. Upon this diagnosis, the patient was switched from D-penicillamine to trientine, with adequate cupriuresis and stabilization of the skin lesion. Prompt diagnosis and management of PPXE in children can limit systemic progression and prevent long-term complications.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Hepatolenticular Degeneration* / diagnosis
  • Hepatolenticular Degeneration* / drug therapy
  • Humans
  • Male
  • Penicillamine* / adverse effects
  • Pseudoxanthoma Elasticum* / chemically induced
  • Pseudoxanthoma Elasticum* / diagnosis
  • Pseudoxanthoma Elasticum* / drug therapy
  • Skin Diseases* / chemically induced
  • Skin Diseases* / diagnosis
  • Skin Diseases* / drug therapy
  • Trientine

Substances

  • Penicillamine
  • Trientine